ICON Central Laboratories partners with FMD to open new laboratory facility in China

NewsGuard 100/100 Score

ICON Central Laboratories - a division of ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries - today announced the opening of a new laboratory facility in Tianjin, China, in partnership with Fountain Medical Development Ltd (FMD). It is the third ICON laboratory in the Asia-Pacific region.

“Our alliance with Fountain Medical Development (FMD) and the launch of this new facility underlines our commitment to satisfying our clients' growing demand for quality central laboratory services in the Asia-Pacific region.”

ICON Central Laboratories China offers 3000 square feet of laboratory space and is located 70 miles from Beijing in Tianjin - one of China's most accessible and technologically advanced cities. It will deliver site support services to clinical investigators throughout China and offers overall benefits including shorter shipping distances between clinical sites and existing laboratory testing facilities which expedites study completion.

The facility will offer a comprehensive menu of testing services that includes: chemistry, haematology, coagulation, immunology and other testing services to meet study-specific requirements. The laboratory received CAP (College of American Pathologists) accreditation in May 2010 and is also NGSP Level I Certified.

Commenting on the announcement, Tom O'Leary, President - ICON Central Laboratories, said: "Our alliance with Fountain Medical Development (FMD) and the launch of this new facility underlines our commitment to satisfying our clients' growing demand for quality central laboratory services in the Asia-Pacific region."

Dan Zheng, CEO, FMD, added: "Partnering with ICON Central Laboratories gives the FMD team access to the resources, systems and infrastructure of a large international organisation involved in the management of both large global trials and localised studies. In return, our local knowledge and experience will be utilised by ICON as they work to provide clients with a faster and more cost efficient service."

ICON has been operational in the Asia-Pacific region for over 10 years, where it already employs over 800 staff, with existing laboratory facilities situated in Bangalore and Singapore.

Source:

 ICON Central Laboratories

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Updated vaccine provides strong immune response against previous and emerging SARS-CoV-2 variants